TABLE 3.
Viable counts of bifidobacteria in fecal cultures supplemented with NDO and clindamycin
| Treatment | Bifidobacterial viable counts (log10 CFU ml−1)a |
||||
|---|---|---|---|---|---|
| 0 h | 6 h | 12 h | 24 h | 48 h | |
| Control | 7.8 ± 0.6 | 8.2 ± 0.4 | 8.2 ± 0.5 | 8.1 ± 0.5 | 7.6 ± 0.6 |
| NDO treatment group | |||||
| FOS | 7.8 ± 0.6 | 8.7 ± 0.3 | 8.7 ± 0.4 | 8.6 ± 0.4 | 7.8 ± 0.7 |
| GOS | 7.8 ± 0.6 | 8.8 ± 0.3 | 8.7 ± 0.5 | 8.5 ± 0.4 | 6.8 ± 1.5 |
| Inulin | 7.9 ± 0.7 | 8.6 ± 0.4 | 8.6 ± 0.5 | 8.3 ± 0.2 | 7.6 ± 0.9 |
| Mean | 7.8 ± 0.6 | 8.7 ± 0.3 | 8.7 ± 0.4b | 8.5 ± 0.3 | 7.4 ± 1.0 |
| Clindamycin control | 8.0 ± 0.6 | 6.2 ± 1.3 | 6.0 ± 1.2 | 5.5 ± 1.1 | 5.1 ± 0.9 |
| Clindamycin + NDO treatment group | |||||
| Clindamycin + FOS | 7.8 ± 0.6 | 5.0 ± 0.3 | 4.3 ± 0.2 | 3.1 ± 0.8 | 3.3 ± 0.9 |
| Clindamycin + GOS | 7.8 ± 0.6 | 5.1 ± 0.5 | 4.3 ± 0.3 | 3.5 ± 0.7 | 3.4 ± 1.0 |
| Clindamycin + Inulin | 7.9 ± 0.7 | 5.5 ± 1.2 | 5.1 ± 1.3 | 4.4 ± 1.7 | 4.2 ± 1.3 |
| Mean | 7.8 ± 0.6 | 5.2 ± 0.7 | 4.5 ± 0.8c | 3.6 ± 1.2 | 3.6 ± 1.0 |
a
Mean ± standard deviation (n = 3).
b
There was a significant difference between the control and the NDO treatment group as determined by analysis of variance (P ≤ 0.001).
c
There was a significant difference between the clindamycin control and the group that was treated with clindamycin and NDO (P ≤ 0.05).